BMT CTN Protocol 0302

Initial Systemic Treatment of Acute GVHD: A Phase II Randomized Trial Evaluating Etanercept, Mycophenolate Mofetil (MMF), Denileukin Diftitox (Ontak), and Pentostatin in Combination with Corticosteroids

Below are protocol-related doucments, which may be periodically updated.

            Protocol Chair: Dan Weisdorf, MD (612-624-3101)

            Protocol Officer: Marcelo Pasquini, MD (414-805-0700)

            Protocol Coordinator: Kristin Knust (301-251-1161)

            Medical Monitor: Mary Eapen, MD (414-805-0700)

The BMT CTN #0302 study met its target accrual of 180 patients and closed enrollment on March 24, 2008.